KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
cetuximab Resistant: A1 - Approval
|
cetuximab Resistant: A1 - Approval
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
panitumumab Resistant: A1 - Approval
|
panitumumab Resistant: A1 - Approval
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
KRAS A146
|
CRC
|
KRAS A146
|
CRC
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|